These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 16495804

  • 1. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-gamma.
    Yi T, Cuchara L, Wang Y, Koh KP, Ranjbaran H, Tellides G, Pober JS, Lorber MI.
    Transplantation; 2006 Feb 27; 81(4):559-66. PubMed ID: 16495804
    [Abstract] [Full Text] [Related]

  • 2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 3. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct 15; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 4. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan 15; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

  • 5. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 15; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 6. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F, Sparacino V, Altieri P, Rigotti P, Calabrese S, Poli M, Vinti V, Segoloni GP.
    Transplant Proc; 2005 Mar 15; 37(2):827-9. PubMed ID: 15848545
    [Abstract] [Full Text] [Related]

  • 7. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
    Transpl Int; 2007 Oct 15; 20(10):875-83. PubMed ID: 17854445
    [Abstract] [Full Text] [Related]

  • 8. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug 15; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 9. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M, Liu S, Strobl M, Schmaderer C, Baumann M, Heemann U, Lutz J.
    Transplant Proc; 2008 Dec 15; 40(10):3731-6. PubMed ID: 19100477
    [Abstract] [Full Text] [Related]

  • 10. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
    Oberbauer R, Hutchison B, Eris J, Arias M, Claesson K, Mota A, Kreis H, Kleinman L, Wang F, Chen J, Revicki DA, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Apr 27; 75(8):1277-85. PubMed ID: 12717216
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
    Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C.
    Transplantation; 2009 May 15; 87(9):1290-9. PubMed ID: 19424027
    [Abstract] [Full Text] [Related]

  • 12. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
    Li J, Xia J, Zhang K, Xu L.
    J Surg Res; 2009 Nov 15; 157(1):81-90. PubMed ID: 19577762
    [Abstract] [Full Text] [Related]

  • 13. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 15; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 14. The effect of sirolimus in the development of chronic allograft nephropathy.
    Gürkan A, Kaçar S, Erdoğdu U, Varilsüha C, Kandemir G, Karaca C, Akman F.
    Transplant Proc; 2008 Dec 15; 40(1):114-6. PubMed ID: 18261561
    [Abstract] [Full Text] [Related]

  • 15. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Clin Transplant; 2007 Dec 15; 21(3):330-6. PubMed ID: 17488381
    [Abstract] [Full Text] [Related]

  • 16. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine.
    Reis F, Parada B, Teixeira de Lemos E, Garrido P, Dias A, Piloto N, Baptista S, Sereno J, Eufrásio P, Costa E, Rocha-Pereira P, Santos-Silva A, Figueiredo A, Mota A, Teixeira F.
    Transplant Proc; 2009 Apr 15; 41(3):868-73. PubMed ID: 19376375
    [Abstract] [Full Text] [Related]

  • 17. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
    Piao SG, Bae SK, Lim SW, Song JH, Chung BH, Choi BS, Yang CW.
    Transplantation; 2012 Feb 27; 93(4):383-9. PubMed ID: 22267156
    [Abstract] [Full Text] [Related]

  • 18. Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.
    Hong ME, Hong JC, Stepkowski S, Kahan BD.
    Transplant Proc; 2005 Dec 27; 37(10):4254-8. PubMed ID: 16387092
    [Abstract] [Full Text] [Related]

  • 19. Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.
    Yi T, Rao DA, Tang PC, Wang Y, Cuchara LA, Bothwell AL, Colangelo CM, Tellides G, Pober JS, Lorber MI.
    Transplantation; 2008 Sep 15; 86(5):719-27. PubMed ID: 18791454
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.
    J Am Soc Nephrol; 2006 Feb 15; 17(2):581-9. PubMed ID: 16434506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.